MYCN and Nijmegen breakage syndrome: We believe that this epigenetic treatment approach could have important implications for the future development of immune checkpoint inhibitor therapy in NB to overcome the current limitations.17 18 Our limited data on NB cell lines also suggest that EHMT inhibition alone might be sufficient for MYCN-low and MYC-low NBs, but this would require future in-depth studies.